par Schwarze, Julia Katharina;Garaud, Soizic
;Jansen, Yanina J L;Awada, Gil;Vandersleyen, Valerie;Tijtgat, Jens;de Wind, Alexandre;Kristanto, Paulus;Seremet, Teofila T.C.;Willard-Gallo, Karen;Neyns, Bart
Référence Cancers (Basel), 14, 3
Publication Publié, 2022-01-01

Référence Cancers (Basel), 14, 3
Publication Publié, 2022-01-01
Article révisé par les pairs
Résumé : | Optimal dosing and duration of adjuvant treatment with PD-1 and CTLA-4 immune checkpoint inhibitors have not been established. Prior to their regulatory approval we investigated a low-dose regimen of nivolumab with or without ipilimumab in a sequential dual-cohort phase II clinical trial. |